Kairos Pharma, LTD. (KAPA) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$5.4M, or -$2.10 per diluted share. Operating activities generated -$3.4M of cash. At fiscal year end, Kairos Pharma held $6.5M in total assets against $199,000 in total liabilities, including $4.5M of cash and equivalents.
Open the full interactive Kairos Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
Kairos Pharma Key Stats
| Share Price | $0.83 |
|---|---|
| Market Cap | $2.5M |
| 52-Week Range | $0.81 – $9.03 |
| Shares Outstanding | 3.1 million (basic, 2026 Q2) |
Kairos Pharma Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Operating Income | -$2.3M | -$5.6M |
| Pre-Tax Income | -$2.6M | -$5.4M |
| Net Income | -$2.6M | -$5.4M |
| Diluted EPS | -$1.61 | -$2.10 |
Kairos Pharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | -$1.4M | -$1.4M | -$1.7M | -$1.4M |
| Diluted EPS | -$0.49 | -$0.07 | -$0.56 | -$0.42 |
Kairos Pharma Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | — | $4.5M |
| Current Assets | $4.2M | $5.4M |
| Total Assets | $5.8M | $6.5M |
| Current Liabilities | $992,000 | $199,000 |
| Total Liabilities | $992,000 | $199,000 |
| Shareholders' Equity | $4.8M | $6.3M |
Kairos Pharma Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$4.0M | -$3.4M |
| Cash From Financing | $5.1M | $6.7M |
Figures from Kairos Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Kairos Pharma financials page for every line item.
Kairos Pharma Company Profile
| Ticker | KAPA |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Los Angeles, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001962011 |
Frequently Asked Questions
What was Kairos Pharma's net income in fiscal 2025?
Kairos Pharma reported net income of -$5.4M for fiscal 2025.
What was Kairos Pharma's earnings per share (EPS) in fiscal 2025?
Kairos Pharma's diluted EPS was -$2.10 for fiscal 2025 (adjusted for any later stock splits).
How many shares of Kairos Pharma are outstanding?
Kairos Pharma reported a weighted average of 3.1 million basic shares outstanding in 2026 Q2.
What is Kairos Pharma's market cap?
Based on its latest closing price, Kairos Pharma (KAPA) has a market capitalization of about $2.5M.
When does Kairos Pharma's fiscal year end?
Kairos Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is Kairos Pharma headquartered?
Kairos Pharma lists its business address in Los Angeles, California in its SEC filings.